ロード中...
Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017
IMPORTANCE: Sipuleucel-T was the first therapeutic cancer vaccine approved by the US Food and Drug Administration (FDA) in 2010. Although almost a decade has passed since its approval for the treatment of asymptomatic or minimally symptomatic castration-resistant prostate cancer (CRPC), there remain...
保存先:
| 出版年: | JAMA Netw Open |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Medical Association
2019
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6694390/ https://ncbi.nlm.nih.gov/pubmed/31411714 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2019.9249 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|